Dianthus Therapeutics (STU:87E) OCF Margin %: -6,240.00% (As of Mar. 2026)


STU:87E Dianthus Therapeutics Inc STU:87E
22 GF Score
Price €82.00
GF Value €2.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics OCF Margin %?

Dianthus Therapeutics STU:87E 22 OCF Margin % is -6,240.00% as of Mar. 2026. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 951 Biotechnology companies, Dianthus Therapeutics ranks worse than 94.01% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Dianthus Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was €-24.96 Mil. Dianthus Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.40 Mil. Therefore, Dianthus Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was -6,240.00%.

As of today, Dianthus Therapeutics's current OCF Yield % is -2.53%.

The historical rank and industry rank for Dianthus Therapeutics's OCF Margin % or its related term are showing as below:

STU:87E' s OCF Margin % Range Over the Past 10 Years
Min: -6338.9   Med: -1253.89   Max: -453.02
Current: -9749.78

During the past 5 years, the highest OCF Margin % of Dianthus Therapeutics was -453.02%. The lowest was -6338.90%. And the median was -1253.89%.

STU:87E's OCF Margin % is ranked worse than
94.01% of 951 companies
in the Biotechnology industry
Industry Median: -64.23 vs STU:87E: -9749.78

Dianthus Therapeutics OCF Margin % Related Terms

Dianthus Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics OCF Margin % Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
-671.13 -452.99 -1,304.59 -1,253.98 -6,337.95

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,375.28 -12,403.59 -7,724.93 -16,511.52 -6,240.00

STU:87E vs CAI, TNGX, MANE: OCF Margin % Comparison

For the Biotechnology subindustry, Dianthus Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dianthus Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's OCF Margin % falls into.


STU:87E
22GF Score
Dianthus Therapeutics Inc STU:87E
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Dianthus Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-110.217/1.739
=-6,337.95 %

Dianthus Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-24.96/0.4
=-6,240.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -6,240.00% mean?
Dianthus Therapeutics (STU:87E) has a OCF Margin % of -6,240.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Dianthus Therapeutics and its competitors. According to the industry distribution chart, Dianthus Therapeutics ranks #894 out of 951 companies in the Biotechnology industry, placing it in the top 94%.
Is Dianthus Therapeutics' OCF Margin % too high?
Dianthus Therapeutics' current OCF Margin % is -6,240.00%. Based on the distribution chart, Dianthus Therapeutics ranks #894 out of 951 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' OCF Margin % compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #894 out of 951 companies for OCF Margin %. This places Dianthus Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current OCF Margin % is -6,240.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current OCF Margin % is -6,240.00%. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current OCF Margin % is -6,240.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:87E:

  • OCF Margin %: -6,240.00%
  • GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges DNTH:USA
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for STU:87E

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.00
Price
€2.53
GF Value